(GLMD) to Present at the Metabolic Leaders’ Forum 2015

TEL AVIV, Israel, March 17, 2015  — Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (“Galmed”), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones, announced today that Dr. Maya Halpern, Galmed’s Chief Medical Officer, will present at the Metabolic Leaders’ Forum 2015, which will be held in Boston beginning on Tuesday, March 24, 2015.  Dr. Halpern’s presentation will be given on Wednesday, March 25, 2015, at 3:05pm Eastern Time/12:05pm Pacific Time, on the topic of “Treatment of Non-Alcoholic Fatty Liver Diseases:  How early is early?”

“I am excited to present our pioneering strategy of developing aramchol to treat Non-Alcoholic Steato-Hepatitis, or NASH, patients not only as a liver-related disorder, but also as a significant factor in the worsening of metabolic syndrome,” commented Dr. Halpern.  “We also believe our compelling safety data to date differentiates aramchol as a possible chronic treatment for NASH patients with a high risk of cardiovascular disease.”

Dr. Halpern concluded, “The Metabolic Leaders’ Forum is a great opportunity for Galmed to gain greater exposure to, and interaction with the pharmaceutical industry’s relevant stakeholders.”

Galmed’s ARREST study is a multi-center, randomized, double-blind, placebo-controlled, dose-ranging Phase IIb clinical trial of aramchol.  The study’s primary end-point is a statistically significant reduction of liver fat content measured by MRS, and the study’s secondary end-points are the complete resolution of NASH, as measured by two biopsies at the beginning and end of the study, and improvement of the Non-Alcoholic Fatty Liver Diseases activity score, as well as an improvement in the markers of liver inflammation and various metabolic biomarkers.

About Galmed Pharmaceuticals Ltd.
Galmed is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel, once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or FABACs. Galmed believes that its product candidate, aramchol, has the potential to be a disease modifying treatment for fatty liver disorders, including NASH, which is a chronic disease that Galmed believes constitutes a large unmet medical need.

Forward-Looking Statements
This press release includes forward-looking statements. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Applicable risks and uncertainties include those identified under the heading “Risk Factors” included in the registration statement on Form F-1 (File No. 333 -193792), initially filed with the Securities and Exchange Commission, or the SEC, on February 6, 2014 and declared effective by the SEC on March 12, 2014, and in other filings that Galmed has made and may make with the SEC in the future. The forward-looking statements contained in this press release reflect Galmed’s current views with respect to future events, and Galmed does not undertake and specifically disclaims any obligation to update any forward-looking statements.